How can neuropharmacology help to maintain and restore cognition and memory function?
What drug and non-drug approaches are there to stimulate the brain?
These are just some of the questions that our upcoming webinar, Neuropharmacology of dementia and other brain diseases, will seek to answer.
Join Dr. Andrea Kwakowsky, University of Galway and Professor Keith Murphy, UCD, on Thursday, 13 March at 11.00 am!
To register for this webinar, click HERE.
Dr Andrea Kwakowsky will speak on The excitatory and inhibitory neuronal networks as therapeutic targets in neurological disorders. In this talk, Dr Kwakowsky will present evidence of the remodelling of excitatory and inhibitory neuronal networks in the Alzheimer’s disease brain and other neurological conditions. Some of the promising therapeutic approaches will be discussed that are currently under investigation in her lab.
Professor Keith Murphy will talk about Investigating how memory works: In search of better cognition enhancing drugs. This talk will introduce what we know and what we are finding out about how our brain's store memories. The talk will explore how we might be able to use that knowledge to develop new drugs that can enhance and protect our memory function against dementia and other brain diseases.
Dr Andrea Kwakowsky is a lecturer in pharmacology at the School of Medicine, University of Galway. Her primary research interest is in the molecular and cellular basis of brain function in Alzheimer's disease (AD), Huntington's disease (HD) and Multiple sclerosis (MS). Dr Kwakowsky’s lab conducts multi-disciplinary research that aims to transform the understanding of the pathological mechanisms of neurodegenerative diseases and find novel drug targets and therapeutic strategies, and to understand the underlying pathology of disorders such as AD, and to determine whether manipulation of specific neuronal pathways could be part of an effective treatment.
Keith Murphy is Professor of Neuropharmacology at the School of Biomolecular and Biomedical Science, University College Dublin, where he runs the Neurotherapeutics Research Group. This group is dedicated to understanding brain function and dysfunction, and the identification of novel drug targets for the treatment of neurological and neurodegenerative diseases such as drug addiction, depression, anxiety, schizophrenia, cognitive decline and multiple sclerosis. Professor Murphy's research uses several different approaches including animal models of behaviour, in vivo site-directed interruption of function, in vitro cell and organoid culture techniques, transcriptomics and proteomics, and computational neuroscience, to develop these much-needed new neurotherapeutics.